Research
Evidence-based research
Every sourced explainer this desk publishes on GLP-1 medicines, grouped by the question it answers. 52 pieces, 228 references between them, each tied to a primary source — a trial, a label, or an FDA database — and cited inline rather than gestured at. Most recently updated .
Looking for the companies rather than the evidence? Every program we track is scored and written up on the full deal review index — that is where this page used to live, and where the briefs are now. If a cost guide sent you here, the Eden review, the SnagRx review and the yourEra review show how one program's published price is read in practice.
52 articles.
- Zepbound Cost Without Insurance: What You Actually Pay in 2026Zepbound self-pay starts at $299 — but that is the starting dose. Here is the real dose ladder, the 45-day catch, and what 28-day billing costs you.3 references
- Wegovy Cost Without Insurance: The $199 Offer and What Follows ItWegovy pen self-pay: $199 per eligible fill for up to two fills, then $349. Pills cost $149–$299 by dose. Compare renewal and subscription terms.4 references
- Ozempic Cost Without Insurance: The Ladder Behind the $199Ozempic self-pay: $199 per eligible fill for up to two fills, then $349 or $499 by dose. Compare tablet prices and savings-card terms.4 references
- Mounjaro Cost Without Insurance: Why the $499 Card Is Not for YouMounjaro's $499 savings card requires commercial insurance that does not cover it. If you are truly uninsured you do not qualify. Here is what does apply.3 references
- Compounded Tirzepatide Cost: What You Actually Pay per MonthCompare compounded tirzepatide offers, ongoing monthly rates, dose increases and plan commitments. Advertised prices are not always comparable monthly bills.6 references
- Zepbound Savings Card: Who Gets $25, Who Pays $499Lilly's Zepbound card means $25 only if your commercial plan covers it, $499 if it doesn't, and nothing on Medicare or Medicaid. The caps, fills and traps.4 references
- Does Medicaid Cover GLP-1s? State Rules and Coverage ExceptionsMedicaid GLP-1 coverage varies by state, diagnosis and age. California, North Carolina and Pennsylvania examples, plus the limits of BALANCE.6 references
- The Cheapest Legit Way to Start GLP-1 in 2026Cash-pay GLP-1 starts under $99/mo in 2026 — but 'cheapest' only counts if it's legit. Here's how to get a low price from a verified pharmacy.3 references
- GLP-1 Drug Interactions: What to Tell Your PrescriberInsulin, sulfonylureas, oral contraceptives, and other oral medications can all be affected by GLP-1 treatment. Here's what the FDA labeling actually says.4 references
- Oral GLP-1 Pills vs Injections: What the Trial Evidence ShowsFoundayo (orforglipron) and oral semaglutide put a pill next to the needle. Here's how their trial results actually compare to Wegovy and Zepbound injections.10 references
- GLP-1 Shortage Status: What the FDA Actually Declared and WhenThe FDA declared the tirzepatide and semaglutide shortages resolved in late 2024 and early 2025 — the exact orders, dates, and what changed for compounders.6 references
- GLP-1 and Alcohol: What the Evidence Actually ShowsWhat the 2025 and 2026 semaglutide trials found in alcohol use disorder, why they do not establish drinking safety, and questions for your prescriber.6 references
- GLP-1 and Muscle Loss: What the Body-Composition Data ShowsDXA data from the SURMOUNT-1 substudy and a 2025 meta-analysis show roughly a quarter of GLP-1 weight loss is lean mass. Here's what that does and doesn't mean.2 references
- GLP-1 and Dental Side Effects: What "Ozempic Teeth" Claims Actually Have Behind ThemA 2023 case series and a 2025 mechanistic review documented real dry-mouth cases linked to semaglutide. Here's the evidence behind the "Ozempic teeth" trend.3 references
- GLP-1 and Sleep Apnea: The SURMOUNT-OSA Trial EvidenceTirzepatide cut breathing interruptions by roughly 25 events per hour in a 2024 trial — real enough that the FDA approved Zepbound to treat sleep apnea.2 references
- Semaglutide vs Liraglutide: Cost and Trial Evidence ComparedCompare semaglutide and liraglutide trial results, daily versus weekly dosing, lean-mass evidence, and the costs to check before choosing a prescription.5 references
- GLP-1 Microdosing: What the Evidence Actually SupportsDaily semaglutide trial doses are not weekly microdoses. A review of dose-ranging evidence, standard titration and the limits of GLP-1 microdosing claims.4 references
- The Medicare GLP-1 Bridge Program: What It Actually Covers in 2026Eligible Medicare Part D members pay $50 through the GLP-1 Bridge. Check the drugs, BMI thresholds, exclusions and costs outside the Part D benefit.4 references
- Retatrutide: Is It Available Yet, and Is It Safe to Buy Right Now?Retatrutide has Phase 3 results but remains investigational. Review the trial populations, FDA compounding warning, and what online listings actually establish.8 references
- GLP-1 and Kidney Disease: The FLOW Trial EvidenceSemaglutide cut major kidney disease events by 24% in a 2024 randomized trial large enough to change the FDA label. Here's what it actually measured.2 references
- CagriSema: What the REDEFINE Trial Data Actually ShowCagriSema trial results, the REDEFINE 4 comparison with tirzepatide, and its FDA filing. What the evidence can tell you before considering a seller.5 references
- GLP-1 and Bone Density: What the Evidence ShowsA 25-study analysis in type 2 diabetes found improved bone density and an uncertain fracture-risk estimate. See its findings and limits.1 reference
- Is a GLP-1 Prescription HSA or FSA Eligible? Here's the Actual IRS RuleThe IRS allows weight-loss treatment as a medical expense only when it treats a diagnosed disease. The exact rule, and how it applies to a GLP-1 prescription.3 references
- Does Ozempic Cause Depression? What the Evidence Actually ShowsFDA’s January 2026 review found no increased risk of suicidal behavior or ideation with GLP-1 drugs. What that means for earlier studies and mood concerns.3 references
- Vyvron Review: 13 Charges a Year, Not 12Vyvron bills every four weeks while printing a monthly price. At $199 that is $2,587 a year, not $2,388 — and tirzepatide has no monthly rung at all.2 references
- How to Choose a GLP-1 Provider Without OverpayingA savings-first checklist for picking a GLP-1 program: read the real 12-month price, verify the pharmacy, match the molecule, and skip teaser bait.3 references
- Compounded vs Brand-Name GLP-1: Which Actually Saves You MoneyCompare compounded GLP-1 offers with current brand-name cash-pay routes, insurance costs and dose terms to see which may cost less for your prescription.3 references
- How to Spot a GLP-1 Teaser-Rate TrapThe $99-first-month-then-triples pattern is the most expensive GLP-1 trap. Here's how to spot the teaser rate and price the deal you'll actually pay.2 references
- How to Verify a Compounding Pharmacy Is Legitimate: A Practical ChecklistCheck a compounding pharmacy’s state license, prescription rules and certification claims, and learn what those checks do and do not establish.5 references
- Is Compounded Semaglutide or Tirzepatide Still Legal in 2026?Compounded GLP-1 access is narrower after shortages ended. Understand patient-specific prescribing, 503A vs 503B, and FDA's September 2026 warning.7 references
- TrumpRx GLP-1 Prices: Wegovy, Zepbound and FoundayoCompare TrumpRx GLP-1 offers with NovoCare and LillyDirect: starting vs ongoing prices, refill deadlines, government insurance and prescription access.12 references
- Semaglutide vs Tirzepatide: Comparing Cost and EvidenceCompare semaglutide and tirzepatide trial results, formulation differences and full ongoing costs with your prescriber's treatment plan in mind.4 references
- Is Cheap Compounded GLP-1 Safe? How to Vet a Low PriceA low compounded GLP-1 price can be legit or a red flag. Here's how 503A/503B, LegitScript, and FDA compounding rules help you vet the source.2 references
- Does Insurance Cover Zepbound? Check the Plan Before the PriceZepbound coverage depends on your plan, diagnosis and prior authorization. How to check your benefit, appeal a denial and compare the real pharmacy price.4 references
- Do GLP-1 Manufacturer Savings Cards Actually Lower the Price?Compare GLP-1 commercial copay cards, uncovered-plan discounts and self-pay offers. Eligibility, savings caps and ongoing prices matter more than the headline.10 references
- GLP-1 Side Effects: What the STEP and SURMOUNT Trials Actually ReportedNausea, vomiting, diarrhea, discontinuation rates — the real percentages from the semaglutide and tirzepatide obesity trials and FDA labeling, not guesswork.4 references
- GLP-1 Dosing and Titration: How the Schedule Actually WorksSemaglutide and tirzepatide don't start at the maintenance dose. Here's the actual FDA-labeled titration schedule for Wegovy, Ozempic, Mounjaro, and Zepbound.4 references
- GLP-1 and Pregnancy or Breastfeeding: What the Labels Actually SayPregnancy and breastfeeding advice differs by GLP-1 product and formulation. Compare semaglutide washout guidance, lactation data and tirzepatide precautions.5 references
- Semaglutide vs Tirzepatide: Comparing Side Effects and TolerabilitySURPASS-2 put tirzepatide and semaglutide head to head. Here's how nausea, diarrhea, vomiting, and discontinuation rates actually compared in the trial data.3 references
- Wegovy vs Zepbound: What's Actually DifferentDifferent molecules, different manufacturers, a widening gap in approved indications. Here's the head-to-head trial data and what each brand actually treats.3 references
- Mounjaro vs Zepbound: Same Drug, Different PriceMounjaro and Zepbound are both tirzepatide, made by the same company. Here's why the FDA treats them differently — and why the self-pay prices don't match.5 references
- GLP-1 Boxed Warnings: What the Label Actually SaysThyroid tumor warnings, pancreatitis, gallbladder disease and NAION: what U.S. labels say, plus the European regulator’s semaglutide eye-risk finding.5 references
- GLP-1 and Cardiovascular Risk: The SELECT Trial EvidenceSemaglutide cut heart attacks, strokes, and CV death by 20% in a 17,604-person trial of people without diabetes. Here's what SELECT actually measured.2 references
- Does GLP-1 Cause Hair Loss? What the Evidence Actually ShowsZepbound's label puts hair loss at 4-5% of patients versus 1% on placebo. Here's what the dermatology literature says about why it happens and when it stops.3 references
- GLP-1 and Gallbladder Disease: What the Meta-Analysis of 76 Trials ShowsA pooled analysis of 76 trials and 103,371 patients found gallbladder disease risk more than doubles in weight-loss trials specifically. The actual data.2 references
- GLP-1 Lawsuits: What the Claims Allege, and What the Evidence Actually ShowsTwo active federal litigations now cover GLP-1 injury claims — one for gastroparesis, one for vision loss. What's actually alleged, and the real data behind it.4 references
- Wegovy Pill Cost Without Insurance: $149 Start, Then WhatThe Wegovy pill is $149 for month one only, then $199, then $299 a month at 9 mg and 25 mg. The full dose ladder, the $249 subscription and the pen math.9 references
- GLP-1 and PCOS: What the Fertility and Weight-Loss Evidence ShowsA randomized trial of liraglutide in women with PCOS found meaningful weight loss and improved androgen levels. What the actual RCT data shows — and doesn't.2 references
- Zepbound KwikPen vs Vials: Price, Doses and Which Is CheaperZepbound KwikPen and vials cost the same self-pay: $299, $399, then $449 a month. Where each is sold, what supplies you buy, and which form suits you.7 references
- Foundayo (Orforglipron) Price: Every Dose, With and Without InsuranceFoundayo costs $149 to $349 a month cash by dose, as little as $25 with commercial coverage and Lilly's card, and $50 on Medicare's GLP-1 Bridge.10 references
- Phentermine vs GLP-1: Cost and Effectiveness ComparedA 2026 meta-analysis of 262 trials put phentermine-topiramate's weight loss at 8.1% vs. tirzepatide's 14.9%. The real gap, and where cheap drugs still work.1 reference
- What Happens When You Stop GLP-1 Medication: The Weight-Regain EvidenceWithdrawal data from the STEP 1 extension and SURMOUNT-4 show most lost weight returns within a year of stopping. Here's what the trials actually measured.4 references